BioPharma Dive1 min read
saveLilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
comments(0)
5-min edit window · permanent after that